GlassScriptPhysician profile
Yibo Li
NPI 1861077299
$3,440.37
in general payments reported to CMS, 2019-2025
23 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $349 · 2024: $1,048 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $784.55 | 2023-2025 | Vemlidy, Livdelzi, Biktarvy |
| Abbvie INC. | $333.71 | 2023-2025 | |
| Lilly USA, LLC | $223.70 | 2024-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $169.98 | 2024 | |
| Exact Sciences Corporation | $167.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $157.66 | 2025 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $150.00 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $149.23 | 2025 | Entyvio |
| Novo Nordisk INC | $146.66 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $142.31 | 2025 | Rezdiffra |
| Bridgebio Pharma, INC. | $133.45 | 2025 | Attruby |
| Coloplast Corp | $132.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.32 | 2025 | Jardiance |
| Sanofi Pasteur INC. | $119.73 | 2024 | |
| Evoke Pharma, INC. | $113.20 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $104.77 | 2024 | Xarelto |
| Qol Medical, LLC | $102.10 | 2025 | Sucraid |
| Medtronic, INC. | $52.50 | 2025 | Venaseal |
| Cranial Technologies, INC | $38.45 | 2024 | Doc Band |
| Cipher Pharmaceuticals US LLC | $34.08 | 2025 | Spinosad, Natroba |
| Seqirus USA INC | $26.03 | 2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $20.91 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Janssen Biotech, INC. | $15.32 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yibo Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.